Jens Benn SÃ¸rensen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1331388/publications.pdf

Version: 2024-02-01

30	572	933447 10	642732 23
papers	citations	h-index	g-index

30	30	30	1038
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta OncolÃ³gica, 2022, 61, 409-416.	1.8	11
2	Abstract 2276: High frequency of pathogenic germline variants in patients with malignant mesothelioma. Cancer Research, 2022, 82, 2276-2276.	0.9	0
3	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2022, , .	3.0	7
4	Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative. JTO Clinical and Research Reports, 2021, 2, 100165.	1.1	6
5	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€”Real World Efficacy. Cancers, 2021, 13, 4846.	3.7	19
6	Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005â€“2015): SCAN-LEAF study. Future Oncology, 2021, , .	2.4	2
7	Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma. International Journal of Molecular Sciences, 2021, 22, 12868.	4.1	2
8	Treatment Algorithm for Advanced ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, e156-e157.	1.1	2
9	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences, 2020, 21, 2847.	4.1	25
10	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 569-580.	10.7	117
11	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 2019, 11, 923.	3.7	124
12	Very Early Response Evaluation by PET/MR in Patients with Lung Cancerâ€”Timing and Feasibility. Diagnostics, 2019, 9, 35.	2.6	5
13	18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer. Clinical Nuclear Medicine, 2019, 44, e351-e352.	1.3	0
14	Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. Oncotarget, 2018, 9, 26195-26208.	1.8	35
15	Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)â€”validation in two independent cohorts. PLoS ONE, 2018, 13, e0194609.	2.5	9
16	The prevalence of <scp>ALK</scp> rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. Histopathology, 2017, 70, 889-895.	2.9	3
17	Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. Lung Cancer, 2017, 113, 14-17.	2.0	20
18	Implementation of lung cancer CT screening in the Nordic countries. Acta OncolÃ³gica, 2017, 56, 1249-1257.	1.8	9

#	Article	IF	Citations
19	Long-term Oncologic and Financial Implications of Lung Cancer Screening. Thoracic Surgery Clinics, 2015, 25, 223-229.	1.0	2
20	Use of TUBB3 for patient stratification and prognosis in lung cancer. Lung Cancer Management, 2015, 4, 97-110.	1.5	4
21	Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages Iâ€“IIIA. European Respiratory Review, 2015, 24, 340-355.	7.1	27
22	Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC).. Journal of Clinical Oncology, 2015, 33, e18502-e18502.	1.6	0
23	Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. Anticancer Research, 2015, 35, 6223-9.	1.1	30
24	Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma. Journal of Molecular Diagnostics, 2014, 16, 418-430.	2.8	57
25	Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. European Journal of Cancer, 2013, 49, 2494-2503.	2.8	28
26	Are differentially expressed micro<scp>RNA</scp>s useful in the diagnostics of malignant pleural mesothelioma?. Apmis, 2012, 120, 767-769.	2.0	11
27	Development of Syndrome of Inappropriate Secretion of Antidiuretic Hormone During Progression of Metastatic Breast Cancer. Acta OncolÃ³gica, 1997, 36, 535-537.	1.8	7
28	Phase II study of 4?-iodo-4?-deoxydoxorubicin in non-resectable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1993, 32, 399-402.	2.3	5
29	Phase II study of teniposide in adenocarcinoma of the lung. Cancer Chemotherapy and Pharmacology, 1991, 27, 487-489.	2.3	4
30	Syndrome of Inappropriate Antidiuresis in Smallâ€Cell Lung Cancer. Acta Medica Scandinavica, 1987, 222, 155-161.	0.0	1